Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety Study of Pirtobrutinib in B-Cell Malignancies (J2N-MC-JZNY)
jRCT2011240080Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Open-label, single-arm trial of pirtobrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and non-Hodgkin lymphoma (NHL), sponsored by Eli Lilly and Company. Started May 2025; status: recruiting.
02
Drugs
pirtobrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on jRCT2011240080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011240080.